AptarGroup Earnings Call Transcripts
Fiscal Year 2026
-
A global leader in drug and consumer product dispensing, the company reported $3.8 billion in 2025 revenue, with pharma as its core growth engine. Strong innovation, a diversified pipeline, and sustainability leadership support long-term growth, with margin improvements expected across all segments in 2026.
-
Proprietary drug delivery systems are expanding into new therapeutic areas, with strong growth in injectables and consumer businesses. Operational improvements and regional strategies, especially in China, support resilience. Margin expansion is expected as capacity investments and product mix evolve.
-
Pharma leads with proprietary drug delivery and robust IP, driving two-thirds of EBITDA and a strong, expanding pipeline. Capital allocation remains balanced, with high investment in growth and record share buybacks. Nasal and injectable innovations, digital health partnerships, and global expansion underpin future growth.
Fiscal Year 2025
-
Q4 and full-year 2025 saw strong sales growth and robust innovation, with all segments delivering core sales gains. Margins were pressured by mix and operational issues, but sequential improvement is expected in 2026. Emergency medicine remains a headwind, but pharma, beauty, and closures show positive momentum.
-
Q3 saw adjusted EPS of $1.62, with pharma growth in injectables and drug delivery, offset by consumer healthcare destocking. Emergency medicine faces a 35% revenue decline in 2026, compressing margins, but long-term pharma growth targets remain intact.
-
Raised ROIC and maintained strong growth and margin targets, supported by innovation in Pharma, Beauty, and Closures. Operational efficiency and disciplined capital allocation drive profitability, with free cash flow and shareholder returns set to grow further.
-
Q2 results exceeded guidance with 18% EPS growth and strong performance across all segments, led by Pharma and Closures. Outlook for Q3 is cautious due to naloxone normalization, legal expenses, and ongoing European inventory headwinds, but innovation and capital returns remain robust.
-
Pharma is the primary growth engine, supported by proprietary drug delivery systems, robust sustainability credentials, and a balanced capital allocation strategy. Investments in injectables, digital health, and global operations drive growth, while tariff impacts are mitigated by localized production.
-
Pharma is the fastest-growing and most profitable segment, driving long-term targets upward. Innovation, sustainability, and a resilient global supply chain underpin growth, while disciplined capital allocation supports shareholder returns. Beauty and closures segments are positioned for improved performance as demand and local sourcing trends strengthen.
-
Q1 saw flat core sales and a 3% decline in reported sales due to FX, but adjusted EPS rose 5% year-over-year when neutralizing for currency and tax. Pharma led growth, while beauty and closures showed sequential improvement. Q2 guidance is strong, with limited tariff impact expected.
-
Pharma is the largest and fastest-growing segment, driving value through proprietary technology, global reach, and sustainability leadership. Growth is fueled by innovation in nasal and injectable drug delivery, robust pipeline management, and digital health expansion. Financial targets have been raised, with strong capital allocation and a focus on operational excellence.
Fiscal Year 2024
-
Q4 and full-year results showed strong margin expansion, double-digit EPS growth, and robust cash flow, led by pharma and closures. 2025 guidance anticipates currency and tax headwinds, but underlying business momentum and productivity gains are expected to drive continued earnings growth.
-
Q3 saw 2% core sales growth and 6% higher adjusted EPS, with pharma and closures segments driving performance. Full-year double-digit EPS growth is expected, supported by strong pharma demand, innovation, and disciplined capital allocation.
-
Core sales grew 3% and adjusted EPS rose 12% year-over-year, driven by strong pharma demand and margin expansion. Pharma led with 7% core sales growth, while beauty and closures saw mixed results. Outlook remains positive, with continued investment in innovation and sustainability.